U.S. stock futures showed mixed signals with minor Dow gains. MBX Biosciences fell 5.5% to $19.00 amid public offering news. Upsized public offerings typically pressure stock prices short-term. Market sentiment generally negative with several biotech stocks declining. Similar trends observed in other companies announcing public offerings.
MBX plans to offer 8.5 million shares at $14 to $16 each. The IPO could raise $136 million if priced at the top range. Proceeds will finance clinical studies and pre-clinical research. MBX is currently pre-revenue and loss-making. JPMorgan and others are underwriting the IPO deal.
